Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.

Schneider JS, Gollomp SM, Sendek S, Colcher A, Cambi F, Du W.

J Neurol Sci. 2013 Jan 15;324(1-2):140-8. doi: 10.1016/j.jns.2012.10.024. Epub 2012 Nov 28.

2.

GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding.

Schneider JS, Cambi F, Gollomp SM, Kuwabara H, Brašić JR, Leiby B, Sendek S, Wong DF.

J Neurol Sci. 2015 Sep 15;356(1-2):118-23. doi: 10.1016/j.jns.2015.06.028. Epub 2015 Jun 16.

3.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.

Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW.

Lancet Neurol. 2011 May;10(5):415-23. doi: 10.1016/S1474-4422(11)70073-4. Epub 2011 Apr 7. Erratum in: Lancet Neurol. 2012 Dec;11(12):1021.

PMID:
21482191
4.

GM1 ganglioside in the treatment of Parkinson's disease.

Schneider JS.

Ann N Y Acad Sci. 1998 Jun 19;845:363-73.

PMID:
9668369
5.

GM1 ganglioside in Parkinson's disease: Results of a five year open study.

Schneider JS, Sendek S, Daskalakis C, Cambi F.

J Neurol Sci. 2010 May 15;292(1-2):45-51. doi: 10.1016/j.jns.2010.02.009. Epub 2010 Mar 5.

PMID:
20206941
6.

Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study.

Schneider JS, Roeltgen DP, Mancall EL, Chapas-Crilly J, Rothblat DS, Tatarian GT.

Neurology. 1998 Jun;50(6):1630-6.

PMID:
9633704
7.
8.

GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy.

Schneider JS, Roeltgen DP, Rothblat DS, Chapas-Crilly J, Seraydarian L, Rao J.

Neurology. 1995 Jun;45(6):1149-54.

PMID:
7783880
9.

Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson's disease: the LEAP-study.

Verschuur CV, Suwijn SR, Post B, Dijkgraaf M, Bloem BR, van Hilten JJ, van Laar T, Tissingh G, Deuschl G, Lang AE, de Haan RJ, de Bie RM.

BMC Neurol. 2015 Nov 19;15:236. doi: 10.1186/s12883-015-0491-1.

10.

A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease.

Jankovic J, Hunter C.

Parkinsonism Relat Disord. 2002 Mar;8(4):271-6.

PMID:
12039422
11.

The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.

Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL; PKDS009 Study Group.

CNS Drugs. 2004;18(11):733-46. Erratum in: CNS Drugs. 2005;19(7):633.

PMID:
15330687
13.

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D.

Lancet Neurol. 2010 Jun;9(6):573-80. doi: 10.1016/S1474-4422(10)70106-X. Epub 2010 May 7.

PMID:
20452823
14.

Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.

Timmermann L, Asgharnejad M, Boroojerdi B, Dohin E, Woltering F, Elmer LW.

Expert Opin Pharmacother. 2015;16(10):1423-33. doi: 10.1517/14656566.2015.1049597. Epub 2015 May 22.

PMID:
25997442
15.

Levodopa and the progression of Parkinson's disease.

Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group.

N Engl J Med. 2004 Dec 9;351(24):2498-508.

16.

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.

Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, Massey DH, Mizuno Y, Poewe W, Rascol O, Marek K.

Lancet Neurol. 2013 Aug;12(8):747-55. doi: 10.1016/S1474-4422(13)70117-0. Epub 2013 May 31.

17.

Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.

Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD.

Drugs. 1998;55 Suppl 1:23-30.

PMID:
9483167
18.

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.

Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ; TEMPO Open-label Study Group.

Mov Disord. 2009 Mar 15;24(4):564-73. doi: 10.1002/mds.22402.

PMID:
19086083
19.

Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.

Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L, Juhel N, Schapira AH; Pramipexole ER Studies Group.

Neurology. 2011 Aug 23;77(8):759-66. doi: 10.1212/WNL.0b013e31822affb0. Epub 2011 Aug 10.

PMID:
21832218
20.

Therapeutic effects of GM1 on Parkinson's disease in rats and its mechanism.

Ba XH.

Int J Neurosci. 2016;126(2):163-7. doi: 10.3109/00207454.2014.996640. Epub 2015 Jun 12.

PMID:
25495991

Supplemental Content

Support Center